Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
- Addition of sintilimab to pemetrexed and platinum improved progression-free survival
- Phase 3 eXalt3 study shows significantly longer progression-free survival
- checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab
- Scientists discover curious clues in the war between cf bacteria
- Predicting drought in the American West just got more difficult